Floatz logo

L-5-MTHF

Hypertensive Disorder

Shenzhen Ausa Pharmed Co.,LtdSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Hypertensive Disorder cohort.

Asset / SponsorPhaseRating
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
OLMESARTAN MEDOXOMIL
Virginia Polytechnic Institute and State University
Phase 4BBB

View all 50 →

Same molecule, other indications

L-5-MTHF is also rated in:

homocystinuria due to methylene tetrahydrofolate reductase deficiencyActive
BB
Indicative · Phase 4
65 / 100
View asset →
depressive disorderDormant
B
Indicative · Phase 4
62 / 100
View asset →
major depressive disorderDormant
B
Indicative · Phase 4
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →